121 related articles for article (PubMed ID: 12004273)
1. A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection.
Jacobson MA; Spritzler J; Landay A; Chan E; Katzenstein D; Schock B; Fox L; Roe J; Kundu S; Pollard R;
AIDS; 2002 May; 16(8):1147-54. PubMed ID: 12004273
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/microL.
Jacobson MA; Hardy D; Connick E; Watson J; DeBruin M
J Infect Dis; 2000 Oct; 182(4):1070-6. PubMed ID: 10979901
[TBL] [Abstract][Full Text] [Related]
3. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study.
Lévy Y; Sereti I; Tambussi G; Routy JP; Lelièvre JD; Delfraissy JF; Molina JM; Fischl M; Goujard C; Rodriguez B; Rouzioux C; Avettand-Fenoël V; Croughs T; Beq S; Morre M; Poulin JF; Sekaly RP; Thiebaut R; Lederman MM
Clin Infect Dis; 2012 Jul; 55(2):291-300. PubMed ID: 22550117
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
[TBL] [Abstract][Full Text] [Related]
5. CD40 ligand trimer and IL-12 enhance peripheral blood mononuclear cells and CD4+ T cell proliferation and production of IFN-gamma in response to p24 antigen in HIV-infected individuals: potential contribution of anergy to HIV-specific unresponsiveness.
Dybul M; Mercier G; Belson M; Hallahan CW; Liu S; Perry C; Herpin B; Ehler L; Davey RT; Metcalf JA; Mican JM; Seder RA; Fauci AS
J Immunol; 2000 Aug; 165(3):1685-91. PubMed ID: 10903780
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects.
Angel JB; Jacobson MA; Skolnik PR; Giordano M; Shapiro L; LeBeaut A; Greaves W; Fuchs AC
AIDS; 2000 Nov; 14(16):2503-8. PubMed ID: 11101061
[TBL] [Abstract][Full Text] [Related]
8. Immunological consequences of interleukin 12 administration after autologous stem cell transplantation.
Pelloso D; Cyran K; Timmons L; Williams BT; Robertson MJ
Clin Cancer Res; 2004 Mar; 10(6):1935-42. PubMed ID: 15041709
[TBL] [Abstract][Full Text] [Related]
9. Administration of recombinant human interleukin 12 to chronically SIVmac-infected rhesus monkeys.
Watanabe N; Sypek JP; Mittler S; Reimann KA; Flores-Villanueva P; Voss G; Lord CI; Letvin NL
AIDS Res Hum Retroviruses; 1998 Mar; 14(5):393-9. PubMed ID: 9546798
[TBL] [Abstract][Full Text] [Related]
10. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity.
Rigopoulou EI; Suri D; Chokshi S; Mullerova I; Rice S; Tedder RS; Williams R; Naoumov NV
Hepatology; 2005 Nov; 42(5):1028-36. PubMed ID: 16250037
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells.
Van Herpen CM; Huijbens R; Looman M; De Vries J; Marres H; Van De Ven J; Hermsen R; Adema GJ; De Mulder PH
Clin Cancer Res; 2003 Aug; 9(8):2950-6. PubMed ID: 12912941
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
[TBL] [Abstract][Full Text] [Related]
13. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.
Cebon J; Jäger E; Shackleton MJ; Gibbs P; Davis ID; Hopkins W; Gibbs S; Chen Q; Karbach J; Jackson H; MacGregor DP; Sturrock S; Vaughan H; Maraskovsky E; Neumann A; Hoffman E; Sherman ML; Knuth A
Cancer Immun; 2003 Jul; 3():7. PubMed ID: 12862418
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 12-augmented T cell proliferation of peripheral blood mononuclear cells from HIV-seropositive individuals is associated with interleukin 12 receptor beta 2 upregulation.
Jones ML; Young JM; Huang QR; Puls RL; Webber CA; Benson EM
AIDS Res Hum Retroviruses; 2003 Apr; 19(4):283-92. PubMed ID: 12804004
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial.
Lane HC; Davey V; Kovacs JA; Feinberg J; Metcalf JA; Herpin B; Walker R; Deyton L; Davey RT; Falloon J
Ann Intern Med; 1990 Jun; 112(11):805-11. PubMed ID: 1971503
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
Lenzi R; Rosenblum M; Verschraegen C; Kudelka AP; Kavanagh JJ; Hicks ME; Lang EA; Nash MA; Levy LB; Garcia ME; Platsoucas CD; Abbruzzese JL; Freedman RS
Clin Cancer Res; 2002 Dec; 8(12):3686-95. PubMed ID: 12473577
[TBL] [Abstract][Full Text] [Related]
17. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
Bartlett JA; Benoit SL; Johnson VA; Quinn JB; Sepulveda GE; Ehmann WC; Tsoukas C; Fallon MA; Self PL; Rubin M
Ann Intern Med; 1996 Aug; 125(3):161-72. PubMed ID: 8686973
[TBL] [Abstract][Full Text] [Related]
18. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
Schooley RT; Clumeck N; Haubrich R; Thompson M; Danner SA; van Der Ende ME; Sereni D; Antunes F; Blake D; Myers RE; Tisdale M; Millard J; Mustafa N; Nacci P
Antivir Ther; 2001 Jun; 6(2):89-96. PubMed ID: 11491421
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.
Saag MS; Sonnerborg A; Torres RA; Lancaster D; Gazzard BG; Schooley RT; Romero C; Kelleher D; Spreen W; LaFon S
AIDS; 1998 Nov; 12(16):F203-9. PubMed ID: 9833848
[TBL] [Abstract][Full Text] [Related]
20. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment.
Levy Y; Lacabaratz C; Weiss L; Viard JP; Goujard C; Lelièvre JD; Boué F; Molina JM; Rouzioux C; Avettand-Fénoêl V; Croughs T; Beq S; Thiébaut R; Chêne G; Morre M; Delfraissy JF
J Clin Invest; 2009 Apr; 119(4):997-1007. PubMed ID: 19287090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
